Low Molecular Weight Heparin in Prevention of Restenosis After Angioplasty

Background Heparin, an anticoagulant, possesses antiproliferative effects and has been shown to reduce neointimal proliferation and restenosis following vascular injury in experimental studies. Methods and Results The primary aim of this double-blind multicenter study was to determine if 40 mg Enoxaparin, a low molecular weight heparin, administered subcutaneously once daily for 1 month after successful angioplasty would reduce the incidence of restenosis. Four hundred fifty-eight patients were randomized at nine clinical centers (231 to placebo and 227 to Enoxaparin). The primary end point was angiographic or clinical restenosis. Angiographic restenosis was defined as a loss of 50% of the initial gain as measured by quantitative coronary angiography (QCA) at a core laboratory. In the absence of QCA, clinical evidence of restenosis was defined as death, myocardial infarction, repeat revascularization, or worsening angina. Using the intention-to-treat analysis for all

[1]  U. Tebbe,et al.  Pharmacological therapy after coronary angioplasty , 1990, Klinische Wochenschrift.

[2]  角田 恒和 Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model , 1995 .

[3]  E. Graves,et al.  Advance Data from Vital and Health Statistics of the Centers for Disease Control and Prevention/national Center for Health Statistics , 1994 .

[4]  D. Faxon,et al.  Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials. , 1993, Coronary artery disease.

[5]  A. Buchwald,et al.  Low‐Molecular‐Weight Heparin Reduces Neointimal Proliferation After Coronary Stent Implantation in Hypercholesterolemic Minipigs , 1992, Circulation.

[6]  P. Serruys,et al.  Restenosis after coronary angioplasty: the paradox of increased lumen diameter and restenosis. , 1992, Journal of the American College of Cardiology.

[7]  P J de Feyter,et al.  Quantitative coronary angiography to measure progression and regression of coronary atherosclerosis. Value, limitations, and implications for clinical trials. , 1991, Circulation.

[8]  D. Faxon,et al.  Low molecular weight heparin (enoxaparin) reduces restenosis after iliac angioplasty in the hypercholesterolemic rabbit. , 1991, Journal of the American College of Cardiology.

[9]  M. Webster,et al.  Coronary restenosis: what have we learned from angiography? , 1991, Journal of the American College of Cardiology.

[10]  R. Alexander,et al.  Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty. , 1991, Journal of the American College of Cardiology.

[11]  M. Fishbein,et al.  A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. , 1991, Journal of the American College of Cardiology.

[12]  K. Lehmann,et al.  Paradoxical increase in restenosis rate with chronic heparin use: Final results of a randomized trial , 1991 .

[13]  E. Edelman,et al.  Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Ellis,et al.  Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. , 1989, American heart journal.

[15]  A. Planès,et al.  Prevention of Postoperative Venous Thrombosis: A Randomized Trial Comparing Unfractionated Heparin with Low Molecular Weight Heparin in Patients Undergoing Total Hip Replacement , 1988, Thrombosis and Haemostasis.

[16]  T. Ryan Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Journal of the American College of Cardiology.

[17]  F. Loop,et al.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Circulation.

[18]  M. Samama,et al.  The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg , 1988, Journal of clinical pharmacology.

[19]  Johan H. C. Reiber,et al.  Morphologic and densitometric quantitation of coronary stenoses; an overview of existing quantitation techniques , 1988 .

[20]  D. Faxon,et al.  Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. The National Heart, Lung, and Blood Institute Registry. , 1988, The New England journal of medicine.

[21]  S. Schwartz,et al.  Heparin regulates smooth muscle S phase entry in the injured rat carotid artery. , 1987, Circulation research.

[22]  T. Ryan,et al.  Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. , 1987, Circulation.

[23]  J. Hirsh,et al.  A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. , 1986, The New England journal of medicine.

[24]  R. Rosenberg,et al.  Heparin inhibition of smooth muscle cell proliferation: A cellular site of action , 1986, Journal of cellular physiology.

[25]  A. Clowes,et al.  Kinetics of Cellular Proliferation after Arterial Injury: IV. Heparin Inhibits Rat Smooth Muscle Mitogenesis and Migration , 1986, Circulation research.

[26]  D. Cochran,et al.  Effect of heparin on vascular smooth muscle cells. I. Cell metabolism , 1985, Journal of cellular physiology.

[27]  R. Rosenberg,et al.  Cultured endothelial cells produce heparinlike inhibitor of smooth muscle cell growth , 1981, The Journal of cell biology.

[28]  R. Rosenberg,et al.  Inhibition of Rat Arterial Smooth Muscle Cell Proliferation by Heparin: II. In Vitro Studies , 1980, Circulation research.

[29]  M. Karnovsky,et al.  Inhibition of Rat Arterial Smooth Muscle Cell Proliferation by Heparin: In Vivo Studies with Anticoagulant and Nonanticoagulant Heparin , 1980, Circulation research.

[30]  A. Clowes,et al.  Suppression by heparin of smooth muscle cell proliferation in injured arteries , 1977, Nature.